S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver di

S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver di

NOVELTY – Pharmaceutical composites (I) with nitrosating action capable of modifying the action of enzymes involved in the synthesis and transport of lipids in the liver, comprises as active principle an equimolar mixture of a nitrosable thiol and sodium nitrite, conjunctly dissolved in water, thus generating S-nitrosothiols, which are effective in the treatment and/or prevention of fatty liver diseases and other diseases associated with metabolic syndrome. USE – (I) is useful for the treatment and/or prevention of fatty liver diseases, more specifically nonalcoholic fatty liver disease, obesity, type 2 diabetes mellitus, dyslipidemia, visceral adiposity and hypertension, and other diseases associated with metabolic syndrome (claimed). (I) is useful for the treatment of hepatic steatosis, fibrotic steatohepatitis and cirrhosis. (I) was tested for its ability to treat hepatic steatosis induced by a choline-deficient diet in rats. The results showed that the hydroperoxide concentration in the liver was 0.7plus minus0.2 nmol/g protein (for (I) treated rats) and 3.2plus minus0.4 nmol/g protein (for control treated rats). ADVANTAGE – (I) potentially prevents the development of the nonalcoholic fatty liver disease (NAFLD) or even promote the regression of NAFLD and other diseases associated with the metabolic syndrome after their onset in the patient’s organism. (I) is effective in the treatment and/or prevention of the fatty liver disease, preferably NAFLD. DETAILED DESCRIPTION – INDEPENDENT CLAIMS are included for treatment or prevention of fatty liver diseases, more specifically, the nonalcoholic fatty liver disease and other diseases associated with the metabolic syndrome, comprising administering (I) to the patient by the oral route at daily doses of 4 micronsol to 40 mmol (preferably 0.6 mmol), preferably on a chronic use basis.

Main Application Field

A96 (Medical, dental, veterinary, cosmetic.); B05 (Other organics – aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 – B05.); B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.)

INVENTORS:

GANZAROLLI DE OLIVEIRA MARCELO
PEREIRA DE SOUZA GABRIELA FREITAS
GANZAROLLI DE OLIVEIRA FERNANDO
SOUZA DE OLIVEIRA CLAUDIO PINTAS
VELLOSO LICIO AUGOSTO

132_FIGADO

Patent number: WO2007121545-A1;BR200602397-A;WO2007121545-A8;EP2010164-A1;US2010062059-A1;EP2010164-A4

PATENT STATUS:

GRANTED

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607

This technology profile has been automatically generated.

COMPARTILHE:

TECNOLOGIAS RELACIONADAS: